Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.

P. M. Specenier,D. Van den Weyngaert,C. Van Laer,J. Weyler,J. Van den Brande,M. T. Huizing,J. Dyck,D. Schrijvers,J. B. Vermorken

Annals of Oncology（2007）

引用 16|浏览1

暂无评分

摘要

Background: Radiotherapy (RT) with concurrent chemotherapy is the current standard of care for patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN). Gemcitabine (GEM) is a potent radiosensitizer and in addition has activity as an anticancer agent in SCCHN.

查看译文

关键词

chemoradiation,gemcitabine,head and neck cancer,squamous cell carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要